Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
第五届董事会独立董事专门会议第七次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of the board of directors of a company. It discusses the approval of proposals related to exemption from share lock-up commitments for controlling shareholders and senior management, and a major asset sale and related party transaction plan. The document references relevant laws and regulations and records voting results of the independent directors. It is not a full annual report, audit report, or financial statement. It is not a shareholder meeting announcement or voting result declaration. It is a board/management related document focusing on board decisions and approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it contains substantive content about board resolutions, not just an announcement or notice.
2025-04-25 Chinese
关于控股股东、股东协议转让股份暨控制权拟发生变更的公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a significant shareholding change involving a transfer of nearly 30% of the company's shares from existing shareholders to a new controlling shareholder. It includes extensive information about the parties involved, the share transfer agreement, payment terms, lock-up periods, and regulatory compliance. The content focuses on the change in control and ownership structure of the company, with no financial statements or earnings data presented. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is lengthy and detailed, not a brief announcement or a report publication notice, and it does not fit other categories such as M&A filings or management changes. Therefore, the appropriate classification is MRQ.
2025-04-25 Chinese
关于公司股票交易可能被实施退市风险警示及其他风险警示的第二次提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the potential risk warnings related to its stock trading due to expected negative net assets and losses in the upcoming 2024 annual report. It references specific stock exchange listing rules and warns investors about possible delisting risk and other risk warnings. The document is a risk warning announcement and does not contain the actual annual report or audited financial statements. It is a regulatory announcement about the risk status of the stock, not the report itself. The document length is short (2076 characters) and it serves as a risk warning notice rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and risk warning notice.
2025-04-24 Chinese
关于公司股票交易可能被实施退市风险警示及其他风险警示的提示性公告
Delisting Announcement Classification · 95% confidence The document is a public announcement by the company 绿康生化股份有限公司 regarding the potential risk warnings related to delisting due to negative net assets and losses expected for the fiscal year 2024. It references specific Shenzhen Stock Exchange listing rules about risk warnings and delisting risk indicators. The document does not contain actual financial statements or detailed financial data but rather serves as a risk warning notice about possible future delisting and risk warnings after the 2024 annual report is published. The document length is short (1590 characters) and it is clearly an announcement about potential delisting risk and other risk warnings, not the delisting itself or a full report. Therefore, the most appropriate classification is a Delisting Announcement (DLST) as it warns about the risk of delisting and risk warnings related to stock trading status.
2025-04-23 Chinese
2024年度业绩预告修正公告
Earnings Release Classification · 95% confidence The document is titled as a "2024年度业绩预告修正公告" which translates to "2024 Annual Performance Forecast Revision Announcement." It provides updated profit and loss forecasts for the full fiscal year 2024, including expected net losses and net asset values. The document explicitly states it is a revision to a previously issued earnings forecast and includes risk warnings related to potential stock delisting or risk warnings after the annual report is published. The document length is 2350 characters, which is relatively short and consistent with an announcement rather than a full report. It does not contain actual audited financial statements or detailed financial analysis but rather revised forecast figures and risk disclosures. It also states that the final audited data will be in the 2024 Annual Report. Therefore, this document is an Earnings Release (ER) type, specifically an earnings forecast revision announcement, not the full annual report or audit report itself. FY 2024
2025-04-23 Chinese
关于筹划控制权变更事项的进展暨继续停牌公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about the progress of a control rights change plan and the continuation of stock trading suspension. It discusses the ongoing negotiations for a potential change in control, the impact on stock trading, and regulatory compliance regarding suspension and risk warnings. There are no financial statements, detailed financial data, or report contents included. The document is an update on a corporate event and trading status rather than a financial report or detailed filing. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about corporate control and trading suspension without fitting other specific categories.
2025-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.